In vivo efficacy assessment of the CDK4/6 inhibitor palbociclib and the PLK1 inhibitor volasertib in human chordoma xenografts

BACKGROUND: Management of advanced chordomas remains delicate considering their insensitivity to chemotherapy. Homozygous deletion of the regulatory gene CDKN2A has been described as the most frequent genetic alteration in chordomas and may be considered as a potential theranostic marker. Here, we e...

Descripción completa

Detalles Bibliográficos
Autores principales: Passeri, Thibault, Dahmani, Ahmed, Masliah-Planchon, Julien, El Botty, Rania, Courtois, Laura, Vacher, Sophie, Marangoni, Elisabetta, Nemati, Fariba, Roman-Roman, Sergio, Adle-Biassette, Homa, Mammar, Hamid, Froelich, Sébastien, Bièche, Ivan, Decaudin, Didier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732546/
https://www.ncbi.nlm.nih.gov/pubmed/36505864
http://dx.doi.org/10.3389/fonc.2022.960720

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732546/
https://www.ncbi.nlm.nih.gov/pubmed/36505864
http://dx.doi.org/10.3389/fonc.2022.960720

Ejemplares similares